Post-earnings recap
Reported
Thu, Jan 27, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
This earnings report indicates that while ResMed met EPS expectations, there was no revenue data available for comparison. The stock's decline of 2.66% suggests that investors may be concerned about the lack of revenue details and ongoing supply chain issues. Management's cautious tone reflects the challenges ahead but also a commitment to innovation.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.47 | N/A | +0.00% |
| Revenue | N/A | N/A | N/A |
Management expressed cautious optimism about future opportunities. They acknowledged challenges but are focused on innovation and growth.
Management highlighted ongoing challenges in the supply chain.
They emphasized a focus on innovation and product development.
The team remains committed to long-term growth despite current market conditions.